Genprex Q1 2025 10-Q: Minimal Revenue, Assets Detailed
Ticker: GNPX · Form: 10-Q · Filed: May 12, 2025 · CIK: 1595248
| Field | Detail |
|---|---|
| Company | Genprex, Inc. (GNPX) |
| Form Type | 10-Q |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
**Genprex Q1 2025 10-Q: Barely any revenue, but $24M in assets. Keep an eye on cash burn.**
AI Summary
Genprex, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported minimal revenue for the first quarter of 2025, with $0.001 million in both total revenue and cost of revenue. Total assets were $24.15 million, with current assets at $10.86 million. The filing also details stock-based compensation expenses for the periods ending March 31, 2025 and 2024.
Why It Matters
This filing provides a snapshot of Genprex's financial health at the start of 2025, crucial for investors assessing its operational status and asset base.
Risk Assessment
Risk Level: medium — The company reports very low revenue, indicating a high dependence on funding and potential for significant cash burn.
Key Numbers
- $24.15M — Total Assets (As of March 31, 2025, indicating the company's overall financial size.)
- $10.86M — Current Assets (As of March 31, 2025, showing readily available resources.)
- $0.001M — Total Revenue (For the three months ended March 31, 2025, highlighting minimal sales activity.)
- $0.001M — Cost of Revenue (For the three months ended March 31, 2025, matching revenue and indicating no gross profit.)
Key Players & Entities
- Genprex, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- $24,154,348 (dollar_amount) — Total assets as of March 31, 2025
- $10,860,655 (dollar_amount) — Current assets as of March 31, 2025
- $184,773 (dollar_amount) — Stock-based compensation expense for Q1 2025
FAQ
What was Genprex's total revenue for the first quarter of 2025?
Genprex reported total revenue of $0.001 million for the three months ended March 31, 2025.
What were the company's total assets as of March 31, 2025?
Total assets for Genprex, Inc. amounted to $24,154,348 as of March 31, 2025.
How much stock-based compensation expense did Genprex incur in Q1 2025?
Genprex reported $184,773 in stock-based compensation expense for the three months ended March 31, 2025.
What was the cost of revenue for Genprex in the first quarter of 2025?
The cost of revenue for Genprex was $0.001 million for the three months ended March 31, 2025.
What is Genprex's fiscal year end?
Genprex, Inc.'s fiscal year ends on December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding Genprex, Inc. (GNPX).